MyHealthTest (MHT), a division of ITL Health Group (ASX:ITD) that creates and markets highly innovative direct to consumer pathology testing for major chronic diseases, is very pleased to announce it has been granted accreditation for its testing laboratory to the ISO15189 and NPAAC (National Pathology Accreditation Advisory Council) standards by the National Association of Testing Authorities (NATA) and the Royal College of Pathologists of Australasia (RCPA).
Accreditation to these standards is required by 1 July 2017 for test laboratories to be compliant with a new medical devices regulatory regime for in-vitro diagnostics (IVDs) administered by the Therapeutic Goods Administration (TGA).
MHT’s channel partners have already commented that the accreditation will enhance their ability to market MHT test offerings to their clients and members, as it will do for MHT’s own direct to consumer marketing.
Accreditation is also a major element of the requirements to enable Medicare rebates for MHT’s services, and MHT will pursue these market opportunities in the near future.
NATA/RCPA accreditation has been a core focus for MHT over the last 18 months, and an enormous amount of time has been committed by the company to meet the very high standards required by NATA/RCPA.
In parallel to seeking the accreditation MHT has been working on a suite of three new test panels for chronic conditions: Prostate, Thyroid and Cardiac disease. MHT looks forward to launching these tests in the near future. Like the diabetes market that MHT already provides the HbAc1 test for, these chronic conditions represent significant market opportunities as each affect large numbers of the population.
Nick Cerneaz, General Manager at MyHealthTest commented “With this accreditation in place we are now able to focus our efforts and resources on the delivery of our services to the market. Coupled with leveraging the endorsement of our services provided by this accreditation I believe MHT is extremely well placed to begin to realise the very many opportunities ahead of us.”
Bill Mobbs, ITL Health Group Executive Chairman commented “The MHT team have worked incredibly hard and I would like to congratulate the team on this achievement. NATA/RCPA accreditation is a crucial milestone for MHT and announces the coming of age for the business.”
MyHealthTest, a highly innovative consumer-based pathology testing service, allows individuals to conveniently order the test service online or from pharmacies, collect samples at home, and send samples through the mail for laboratory analysis. Our next-generation pathology testing service is quality controlled to ensure accuracy and reliability, while our online portal offers guaranteed confidentiality and the simple transfer of results to healthcare practitioners or others. MyHealthTest meets the increased global demand for pathology testing services and sets the industry standard for preventative and convenient direct-to-consumer healthcare services.